ITEOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.44 USD | +43.07% |
|
+49.57% | +59.27% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,185 | 1,642 | 694.8 | 391.8 | 627.2 | - | - |
| Enterprise Value (EV) 1 | 1,185 | 1,642 | 694.8 | 391.8 | 627.2 | 627.2 | 627.2 |
| P/E ratio | -11.7 x | 8.2 x | 7.63 x | -3.48 x | -4.78 x | -2.8 x | -4.64 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 4.76 x | 2.6 x | 31.1 x | - | 784 x | 5.4 x |
| EV / Revenue | - | 4.76 x | 2.6 x | 31.1 x | - | 784 x | 5.4 x |
| EV / EBITDA | -26.5 x | 6.69 x | 5.47 x | - | -3.2 x | -3.15 x | - |
| EV / FCF | -46.4 x | 3.21 x | - | -3.67 x | -4.98 x | -5.18 x | - |
| FCF Yield | -2.15% | 31.2% | - | -27.2% | -20.1% | -19.3% | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,045 | 35,274 | 35,575 | 35,785 | 35,966 | - | - |
| Reference price 2 | 33.82 | 46.56 | 19.53 | 10.95 | 17.44 | 17.44 | 17.44 |
| Announcement Date | 3/24/21 | 3/23/22 | 3/15/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 344.8 | 267.6 | 12.6 | - | 0.8 | 116.1 |
| EBITDA 1 | - | -44.7 | 245.5 | 127.1 | - | -196 | -199 | - |
| EBIT 1 | -28.05 | -45.24 | 244.9 | 126.3 | -151.1 | -200.2 | -258 | -276.7 |
| Operating Margin | - | - | 71.03% | 47.2% | -1,199.69% | - | -32,249.19% | -238.38% |
| Earnings before Tax (EBT) 1 | - | -38.09 | 256.5 | 148.7 | -109 | -174.5 | -250.3 | -249.4 |
| Net income 1 | -22.45 | -43.4 | 214.5 | 96.65 | -112.6 | -181.5 | -264 | -166.9 |
| Net margin | - | - | 62.22% | 36.11% | -894.34% | - | -32,996.41% | -143.77% |
| EPS 2 | - | -2.880 | 5.680 | 2.560 | -3.150 | -3.650 | -6.222 | -3.758 |
| Free Cash Flow 1 | - | -25.53 | 512 | - | -106.7 | -126 | -121 | - |
| FCF margin | - | - | 148.49% | - | -847.34% | - | -15,125% | - |
| FCF Conversion (EBITDA) | - | - | 208.53% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 238.65% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/22/20 | 3/24/21 | 3/23/22 | 3/15/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 240.5 | 152.5 | 41.72 | 19.49 | 53.9 | 12.6 | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | 213.7 | - | 3.53 | -15 | 17.61 | -24.71 | -42.4 | -43.06 | - | - | -46 | -50 | -53 | - | - |
| EBIT 1 | 213.5 | 120.8 | 3.335 | -15.2 | 17.38 | -24.93 | -42.62 | -43.28 | -40.15 | -47.23 | -47.84 | -51.48 | -55.09 | -64.84 | -65.95 |
| Operating Margin | 88.78% | 79.21% | 7.99% | -78.03% | 32.25% | -197.94% | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 224 | 119.5 | 8.443 | -1.986 | 22.75 | -14.35 | -33.07 | -33.42 | -28.19 | -36 | -41.74 | -45.17 | -48.91 | -54.98 | -56.09 |
| Net income 1 | 184.9 | 69.58 | 5.626 | 0.991 | 20.45 | -15.55 | -34.3 | -32.24 | -30.55 | -38.22 | -41.25 | -44.68 | -48.42 | -54.98 | -56.09 |
| Net margin | 76.87% | 45.62% | 13.49% | 5.09% | 37.94% | -123.47% | - | - | - | - | - | - | - | - | - |
| EPS 2 | 4.890 | 1.820 | 0.1500 | 0.0300 | 0.5500 | -0.4400 | -0.9600 | -0.9000 | -0.8500 | -1.070 | -0.8000 | -0.8700 | -0.9600 | -1.595 | -1.660 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/22 | 5/12/22 | 8/10/22 | 11/10/22 | 3/15/23 | 5/10/23 | 8/8/23 | 11/7/23 | 3/6/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -25.5 | 512 | - | -107 | -126 | -121 | - |
| ROE (net income / shareholders' equity) | - | -30.2% | 49% | 15.9% | -18.2% | -25.9% | -26.2% | - |
| ROA (Net income/ Total Assets) | - | -23.1% | 34.9% | 11.8% | -15.8% | -22.6% | -23.1% | - |
| Assets 1 | - | 187.6 | 614.6 | 819.8 | 711.3 | 803.2 | 1,143 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | 2.97 | 1 | 1 | - |
| Capex / Sales | - | - | - | - | 23.55% | - | 125% | - |
| Announcement Date | 5/22/20 | 3/24/21 | 3/23/22 | 3/15/23 | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.44
USD
Average target price
34.4
USD
Spread / Average Target
+97.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.27% | 627M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ITOS Stock
- Financials iTeos Therapeutics, Inc.
